Immunochina raised $7.5M to support clinical trials of its CAR-T product for lymphoma.
November 24, 2017 -- Beijing’s Immunochina raised $7.5 million to support clinical trials of its CAR-T product for lymphoma. Formed by three graduates PhD graduates from Tsinghua University in 2015, Immunochina has started a Phase II trial of its CAR-T candidate in Acute Lymphocytic Lymphoma patients and a Phase I test in Diffuse Large B-cell Lymphoma. The company expects its CAR-T product will be more effective that US-developed candidates.
